January 21st 2025
The company will be featuring its sustainable packaging solutions at the event in Paris on Jan. 22–23, 2025.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
The Next Generation of Aseptic Processing Equipment
May 1st 2006The industry has acknowledged only recently the significance of the contamination risk posed by humans. The authors assert that this realization, together with technological advances, will lead to the elimination of human intervention and, hence, improved sterility.
Discovery Laboratories Reports on Surfaxin Manufacturing Issues
April 27th 2006The biotechnology company Discovery Laboratories Inc. (Warrington, PA, www.discoverylabs.com) reports that analysis of ongoing stability data from "Surfaxin" process validation batches indicates that certain stability parameters have not been achieved, and additional process validation batches will likely have to be produced.
Oligonucleotide Boom: Agilent Acquires Manufacturer SynPro; Dalton Completes CGMP Facility
April 27th 2006Agilent Technologies Inc. (Palo Alto, CA, www.agilent.com) announced April 17 that it acquired SynPro Corp. (Boulder, CO), a contract manufacturer of oligonucleotide active pharmaceutical ingredients. Earlier, Dalton Pharma Services (Toronto), announced that it had completed a multi-gram CGMP oligonucleotide production facility.
Scaling down biopharmaceutical operations Part 1: Fermentation
April 1st 2006Creation and qualification of scale-down models are essential for performing several critical activities that support process validation and commercial manufacturing. As shown in Figure 1, these activities include process characterization and production support studies that are performed to evaluate column and membrane lifetimes, demonstrate clearance of host-cell impurities and viruses and troubleshoot manufacturing issues. While the underlying fundamentals are relatively the same as those when scaling up, some unique considerations should be taken when scaling unit operations down.4
Custom Manufacturers Target Chiral Chemistry, Catalysis, and Biosciences
March 2nd 2006Facing still-sluggish market conditions and a changing world order in fine chemicals, the large Western custom manufacturers are responding by building their toolboxes in specialized technologies in chiral chemistry, catalysis, and biosciences and by adjusting their manufacturing networks via streamlining or investment in Asia.
What is Disinfectant Validation?
March 2nd 2006Adding a cleaning step to the field-testing protocol, and combining it with the data generated to register sanitizing and disinfectant agents under FIFRA and the CEN TC 216 work program, produces a sanitation-and-disinfection validation methodology that is cost-effective, simple, and time-saving.
Grow-Through and Penetration of the 0.2/0.22 "Sterilizing" Membranes
March 2nd 2006The authors encourage the investigation into whether the occurrence of grow-through and the diminution in the size of certain organisms when in contact with given liquids are the same phenomenon manifested under different circumstances.